within Pharmacolibrary.Drugs.ATC.N;

model N06AX12
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.0033333333333333335,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.555,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 900,            
    Vdp             = 0.776,
    k12             = 161,
    k21             = 161
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bupropion is an atypical antidepressant used in the treatment of major depressive disorder and as an aid in smoking cessation. It is also used off-label for attention deficit hyperactivity disorder and as an adjunct in bipolar disorder. Bupropion is approved and commonly prescribed today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Chen, G, et al., &amp; Nomikos, G (2018). Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. <i>Clinical pharmacokinetics</i> 57(6) 673–686. DOI:<a href=\"https://doi.org/10.1007/s40262-017-0612-7\">10.1007/s40262-017-0612-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29189941/\">https://pubmed.ncbi.nlm.nih.gov/29189941</a></p></li><li><p>Costa, R, et al., &amp; Dinis-Oliveira, RJ (2019). Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. <i>Drug metabolism reviews</i> 51(3) 293–313. DOI:<a href=\"https://doi.org/10.1080/03602532.2019.1620763\">10.1080/03602532.2019.1620763</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31124380/\">https://pubmed.ncbi.nlm.nih.gov/31124380</a></p></li><li><p>Hanif, N, et al., &amp; Rasool, MF (2023). Clinical pharmacokinetics of nebivolol: a systematic review. <i>Drug metabolism reviews</i> 55(4) 428–440. DOI:<a href=\"https://doi.org/10.1080/03602532.2023.2271195\">10.1080/03602532.2023.2271195</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37849071/\">https://pubmed.ncbi.nlm.nih.gov/37849071</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX12;
